Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $15

Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $20 to $15.
byBenzinga Newsdesk
August 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $20 to $15.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Connexa Sports Technologies Stock?

By Erica Kollmann
January 31, 1:53 PM
According to an SEC filing, on Jan.19, Connexa Sports Technologies entered into securities purchase agreements with three investors for the issuance and sale to each investor of 2,330,200 shares of common stock and pre-funded warrants to purchase an aggregate of 25,169,800 shares of its common stock at a combined purchase price of $0.20 per share of the common stock for an aggregate amount of approximately $16.5 million.

CNXA